
News|Articles|July 1, 2003
Doxorubicin-related CHF more frequent than previously reported
The utility of doxorubicin is limited by the risk of cumulative, dose-related, progressive myocardial damage.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
2
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
3
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
4
Venclexta combination improves survival and lowers hospital stays for AML patients | ASH 2025
5






















































